KP 1339: Clinical Trials

2 trials of KP 1339, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting, 1 withdrawn. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 1, Withdrawn 1
Phase 21Recruiting 1

Follow KP 1339: new trials by email Literature Review of KP 1339 trials Research Report on KP 1339

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BOLD-100 Plus Doxorubicin in Advanced Soft Tissue Sarcomas
BOLD-100, Doxorubicin 75 mg/m^2 - Sarcoma, Soft-tissue, Sarcoma
Phase 1WithdrawnUniversity Health Network, Toronto2026-03-302026-11-13
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
BOLD-100 ± FOLFOX ± Bevacizumab Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI) - Colorectal Cancer, Pancreatic Cancer
Phase 1 / Phase 2RecruitingBold Therapeutics, Inc.2202020-08-282026-10-28

Conditions studied

Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Pancreatic Neoplasms (1)  ·  Sarcoma (1)  ·  Stomach Neoplasms (1)

Sponsors

Bold Therapeutics, Inc. (1)  ·  University Health Network, Toronto (1)

Countries

Canada (2)  ·  Germany (1)  ·  Ireland (1)  ·  Italy (1)  ·  South Korea (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)